This website uses cookies to ensure you get the best experience on our website. Learn more

The risky way to speed up a coronavirus vaccine

x
  • The risky way to speed up a coronavirus vaccine

    9:13

    A Covid-19 vaccine could take a long time. Some scientists are proposing a controversial plan that could get us one faster.

    Become a Video Lab member!

    With thousands of people dying of Covid-19 every day, the sooner a vaccine can be deemed safe and effective, the better. But vaccine development is a lengthy process that isn’t easy to rush, and that’s in part because of the final step in testing any vaccine: the phase III trial. Phase III requires tens of thousands of volunteers, each of whom get either a placebo or an experimental vaccine. The problem is the next part: Vaccine developers have to wait until a statistically significant number of them, going about their lives normally, eventually get naturally infected. This can take years.

    To speed that up, some epidemiologists and scientists are calling for something called a human challenge trial, in which a subject who has been given the vaccine is deliberately infected. This isn’t a new concept; human challenge trials have been used to develop vaccines or treatments for lots of diseases, like cholera, typhoid, malaria, influenza, and common cold viruses. But what sets Covid-19 apart from those diseases is that it currently has no effective treatment. Because it’s so new, we also aren’t fully aware of its long-term health effects. Unlike other human challenge trials, a Covid-19 challenge trial would entail a risk of serious illness — and even death.

    It’s because of those risks that a Covid-19 challenge trial would be limited to the young and healthy, who would be at the lowest risk of harm. But there are questions beyond the ethics. Would artificially infecting someone in a lab setting provide useful information on how to prevent natural infection? Would a study performed on only young and healthy people produce a vaccine that works for everyone? And with some vaccines already far along in their phase III trials, would a human challenge trial do any good at this point?

    Even though no Covid-19 human challenge trials are currently planned, more than 30,000 people from nearly 150 countries have already said they would volunteer for one if the opportunity presented itself. The question is, should we let them?

    Note: The headline on this piece has been updated.
    Previous headline: Would you volunteer to get Covid-19?

    Further reading:

    1DaySooner is the grassroots organization recruiting volunteers for the possibility of a human challenge trial:


    For more of Vox’s coverage on human challenge studies:


    For more on the ethical and acceptance concerns with vaccine development:


    For a history of challenge studies for other diseases:


    For coverage of the typhoid vaccine we mention in the video:


    For coverage of Oxford University’s statement on human challenge trials:


    Vox.com is a news website that helps you cut through the noise and understand what's really driving the events in the headlines. Check out

    Watch our full video catalog:

    Follow Vox on Facebook:

    Or Twitter:

  • x
  • The controversial push to fast-track a COVID-19 vaccine

    9:01

    Human challenge trials could make finding a COVID-19 vaccine faster, but the controversial approach involves exposing volunteers to the virus to see if a potential vaccine works. The National’s Andrew Chang finds out more about this process and the people volunteering to be test subjects. 

    #humanchallengetrials
    #COVIDvaccine
    #vaccines

    Watch The National live on YouTube Sunday-Friday at 9 p.m. ET

    Subscribe to The National:


    Connect with The National online:
    Facebook |
    Twitter |
    Instagram |

    More from CBC News |

    The National is CBC's flagship nightly news program, featuring the day's top stories with in-depth and original journalism, with hosts Adrienne Arsenault and Andrew Chang in Toronto, Ian Hanomansing in Vancouver and the CBC's chief political correspondent, Rosemary Barton in Ottawa.

  • x
  • Coronavirus vaccine: What are human challenge trials? - BBC News

    1:15

    Human challenge trials are regarded by some as a faster way to develop vaccines - but they come with big risks.

    Could they be used to speed up the development of a vaccine for Covid-19?

    BBC Health Correspondent Laura Foster explains how they work.

    Video by Terry Saunders, Megan Fisher and Laura Foster.

    Please subscribe HERE

  • How COVID-19 vaccines are being created quickly without sacrificing safety

    2:17

    Some potential COVID-19 vaccines are already in the third stage of clinical trials. It’s taken a lot of effort and money to squeeze a process that can normally take five years into about 10 months and still be done safely.

    Watch The National live on YouTube Sunday-Friday at 9 p.m. ET

    Subscribe to The National:


    Connect with The National online:
    Facebook |
    Twitter |
    Instagram |

    More from CBC News |

    The National is CBC's flagship nightly news program, featuring the day's top stories with in-depth and original journalism, with hosts Adrienne Arsenault and Andrew Chang in Toronto, Ian Hanomansing in Vancouver and the CBC's chief political correspondent, Rosemary Barton in Ottawa.

  • x
  • What Is An mRNA Coronavirus Vaccine?

    17:03

    More than 30 biotech and pharmaceutical companies around the world are racing to develop a safe Covid-19 vaccine. The process is moving quickly with several vaccine candidates entering late-stage trials in a matter of months. Two of the companies developing a vaccine — Pfizer and Moderna — are utilizing a promising new technology called messenger RNA. Watch the video to learn why experts believe this vaccination method could be a game-changer for getting back to normal.

    CORRECTION At 0:30, this video misstated the number of companies chosen by the White House to receive ‘fast track’ designation from Operation Warp Speed. Vaccine projects from Sanofi, in partnership with GSK, and Novavax also received fast-track status.

    » Subscribe to CNBC:
    » Subscribe to CNBC TV:
    » Subscribe to CNBC Classic:

    About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:
    Subscribe to CNBC PRO:

    #CNBC

    What Is An mRNA Coronavirus Vaccine?

  • How Close Are We To A Coronavirus Vaccine? | NBC News NOW

    1:43

    With the FDA willing to fast track a coronavirus vaccine before phase three trails end, there's a likelihood we could see immunizations by the end of 2020. NBC News' Dr. John Torres weighs in.
    » Subscribe to NBC News:
    » Watch more NBC video:

    NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features NBCNews.com, MSNBC.com, TODAY.com, Nightly News, Meet the Press, Dateline, and the existing apps and digital extensions of these respective properties. We deliver the best in breaking news, live video coverage, original journalism and segments from your favorite NBC News Shows.

    Connect with NBC News Online!
    NBC News App:
    Breaking News Alerts:
    Visit NBCNews.Com:
    Find NBC News on Facebook:
    Follow NBC News on Twitter:
    Follow NBC News on Instagram:

    How Close Are We To A Coronavirus Vaccine? | NBC News NOW

  • x
  • Trump Promises Coronavirus Vaccine Before The End Of 2020 | TODAY

    1:03

    As he accepted the Republican nomination in a speech on the White House grounds, President Trump definitively promised a coronavirus vaccine by the end of the year, if not even sooner. Health officials have called that timeline unrealistic. NBC White House correspondent Peter Alexander reports for TODAY.
    » Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:
    Follow TODAY on Pinterest:

    #Coronavirus #Trump #TodayShow

    Trump Promises Coronavirus Vaccine Before The End Of 2020 | TODAY

  • UK secures early access to 90 million doses of two more COVID-19 vaccine candidates

    2:40

    As 29 global trials remain in play, the UK government hopes that at least one purchase deal already confirmed proves to be safe and effective.

    It comes as Russia announced a vaccine dubbed “Sputnik V”, in reference to their artificial satellite, Sputnik 1 as plans are being started for mass vaccinations later this year.

    Read more here:

    SUBSCRIBE to our YouTube channel for more videos:

    Follow us on Twitter:

    Like us on Facebook:

    Follow us on Instagram:

    For more content go to and download our apps:

    Apple:

    Android

    Sky News videos are now available in Spanish here/Los video de Sky News están disponibles en español aquí

  • UK signs deals to buy experimental coronavirus vaccines - BBC News

    2:40

    The UK government has signed deals to buy two more experimental coronavirus vaccines.

    Ninety million doses have been purchased from a Belgian pharmaceutical company and a US biotech firm.

    The UK now has 340 million doses of six different vaccines on order, enough to give everyone in the country five doses. But it’s still unclear whether any of them will work.

    Clive Myrie presents BBC News at Ten reporting from medical editor Fergus Walsh.

    Please subscribe HERE

  • x
  • Covid-19: When will a vaccine be ready? | The Economist

    11:17

    Around $10bn is being spent on finding a vaccine for coronavirus—it’s not nearly enough. And even when a covid-19 vaccine is found how should it be distributed fairly? Our experts answer your questions.

    00:00 Covid-19: When will a vaccine be ready?
    00:50 Will there ever be a “silver-bullet” vaccine?
    01:41 How long would it take for the whole world to be vaccinated?
    02:25 Who benefits financially from the vaccine?
    03:54 How much will each vaccine cost?
    05:10 What percentage of Americans do you estimate will choose not to get vaccinated, and how much of an issue will this be?
    06:44 In an ideal world, how should a vaccine be optimally distributed?
    07:21 Will new versions of the vaccine be required periodically?
    07:54 Will developing countries receive equal access to the vaccine, or will they be left behind?
    08:50 Should richer countries pay for vaccines in the developing world?
    10:01 How should we respond to crises like this one in the future?

    Further reading:

    Find The Economist’s most recent coverage of covid-19 here:

    Sign up to The Economist’s daily newsletter to keep up to date with our latest covid-19 coverage:

    Listen to “The Intelligence” podcast about the vaccine candidates and equitable distribution:

    How the world can think better about catastrophic and existential risks:

    Read our leader on how people must adapt to living in the covid-19 pandemic era:

    How SARS-CoV-2 causes disease and death in covid-19:

    Covid-19 testing labs are being overwhelmed:

    How the pandemic has shown the urgency of reforming care for the elderly:

    Read about the hunt for the origins of covid-19:

  • Who will get the COVID-19 vaccine first? Doctors weigh in

    4:11

    The race for a COVID-19 vaccine continues as medical experts get closer by the day. The federal government is projecting an effective vaccine for COVID-19 by January 2021 and when we get there the main question will be: who will get priority?


    #COVID19 #vaccine #coronavirus

  • Doctor Explains How Fast a Covid-19 Vaccine Could Be Created | Cause + Control | WIRED

    10:01

    12 to 18 months is the timeline we keep hearing about for a potential Covid-19 vaccine. While this is possible, it would also be the fastest we've ever developed a vaccine. Dr. Seema Yasmin takes a look at the standard timeline for creating a vaccine, from the exploratory stage all the way until manufacturing and quality control. Just how does a Covid-19 vaccine fit into this timeline?

    Still haven’t subscribed to WIRED on YouTube? ►►
    Listen to the Get WIRED podcast ►►

    Get more incredible stories on science and tech with our daily newsletter:

    Also, check out the free WIRED channel on Roku, Apple TV, Amazon Fire TV, and Android TV. Here you can find your favorite WIRED shows and new episodes of our latest hit series Tradecraft.

    ABOUT WIRED
    WIRED is where tomorrow is realized. Through thought-provoking stories and videos, WIRED explores the future of business, innovation, and culture.

    Doctor Explains How Fast a Covid-19 Vaccine Could Be Created | Cause + Control | WIRED

  • FDA commissioner talks coronavirus vaccine development

    2:11

    FDA Commissioner Stephen Hahn spoke with CBS News about how it will handle outside pressure to approve a coronavirus vaccine. Dr. Jon LaPook has more in CBS News' series Racing to a Cure.

    Subscribe to the CBS Evening News Channel HERE:
    Watch Full Episodes of the CBS Evening News HERE:
    Watch the latest installment of On the Road, only on the CBS Evening News, HERE:
    Follow CBS Evening News on Instagram:
    Like CBS Evening News on Facebook HERE:
    Follow the CBS Evening News on Twitter HERE:
    Follow the CBS Evening News on Google+ HERE:

    Get your news on the go! Download CBS News mobile apps HERE:

    Get new episodes of shows you love across devices the next day, stream local news live, and watch full seasons of CBS fan favorites anytime, anywhere with CBS All Access. Try it free!

    ---
    The CBS Evening News premiered as a half-hour broadcast on Sept. 2, 1963. Check local listings for CBS Evening News broadcast times.

  • The COVID Vaccine: When Will It Be Ready?

    14:28

    A discussion of the candidates for a COVID-19 vaccine, the usual timeline for vaccine development, and strategies for dramatically speeding that timeline up.

    ChAdOx1 nCoV-19 Phase 1/2 Trial (The Lancet):

    mRNA-1273 Phase 1 Trial (NEJM):

    The New York Times Vaccine Tracker:

    An alternative vaccine tracker:


    An overview of the most promising COVID vaccine candidates:

  • Moderna clinical trial investigator on hopes for the vaccine

    5:10

    As the number of Covid-19 cases continue to rise, scientists are working hard to create a vaccine. Moderna, one of the most promising Covid-19 vaccine creators, has already started phase three trials in late July. Carlos del Rio, investigator in the Moderna Covid-19 vaccine trials and executive associate dean at Emory University School of Medicine, joins Squawk Box to discuss. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    A coronavirus vaccine that is safe and at least 50% effective would be a “game changer” in battling the pandemic, according to a doctor who is serving as an investigator for Moderna’s clinical trials.

    “Developing vaccines against respiratory virus is incredibly difficult. If you think about the flu vaccine that we use every year, it’s only about 40% to 60% effective,” Dr. Carlos del Rio of Emory University said Tuesday on CNBC’s “Squawk Box.”

    The Food and Drug Administration indicated last month it would authorize a coronavirus vaccine as long as it is safe and at least 50% effective. Dr. Stephen Hahn, the agency’s commissioner, said at the time it would be “unrealistic” to expect a vaccine to be 100% effective.

    A vaccine that is 50% effective means it would reduce the average person’s risk of coronavirus infection by 50%.

    “A 50% efficacy would be transformative. It’s much better than zero, which is what we have right now,” del Rio told CNBC. “So I think it’d really be a game changer if we get a vaccine with 50% or greater efficacy.”

    Dr. Anthony Fauci said, the nation’s leading infectious disease expert, said earlier this month that scientists hope a vaccine to prevent the coronavirus would be at least 75% effective. But the White House health advisor said 50% to 60% efficacy also would be acceptable.

    “You’ve got to think of the vaccine as a tool to be able to get the pandemic to no longer be a pandemic, but to be something that’s well controlled,” Fauci said Aug. 7 during a question-and-answer session with Brown University’s School of Public Health.

    Del Rio said widespread inoculation of a vaccine, even one with 50% efficacy, would help the U.S. achieve so-called herd immunity — the point where enough people have antibodies to fight off the virus and therefore significantly curtail its spread in a population.

    “Between the people that have been infected plus the people that you’ve vaccinated, at 50% you would get there,” said del Rio, a professor in the infectious disease division of Atlanta-based Emory’s medical school. He also is co-director of the Emory Center for AIDS Research.

    It is possible people who receive a coronavirus vaccine — should it receive regulatory approval — may still get infected, del Rio noted. However, being vaccinated could reduce the risk of severe illness from Covid-19, he said.

    “One of the theories is that you may still get infected but you will not develop complications. You will not end up in the hospital. You will not end up in the ICU,” said del Rio. “And that I think also would be quite transformative because you will definitely decrease the morbidity and mortality of the disease.”

    Del Rio is an investigator for Moderna’s potential coronavirus vaccine. The Massachusetts-based biotech firm began its late-stage human trials last month. The National Institutes of Health has been working alongside Moderna, which was the first company to begin human trials in the U.S. in March.

    Moderna has received commitments worth up to nearly $2.5 billion from the U.S. government to aid its vaccine development. Through Operation Warp Speed, the government is providing billions of dollars to various companies that are working on a vaccine.

    As part of those deals, companies are ramping up manufacturing capacity to expedite the deployment of a vaccine, should it prove safe and effective. Del Rio said that is the right strategy.

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:

    For info on the best credit cards go to CNBC Select:


    #CNBC
    #CNBCTV

  • Russia becomes first country to authorize COVID-19 vaccine

    4:08

    ABC News’ Ian Pannell reports on concerns the Russians rushed the clinical trial process. Experts say small trial sizes and lack of data make the safety of the vaccine unclear.

    WATCH the ABC News Live Stream Here:

    SUBSCRIBE to ABC NEWS:
    Watch More on
    LIKE ABC News on FACEBOOK
    FOLLOW ABC News on TWITTER:

    #ABCNLPrime #Russia #COVID-19 #Vaccine

  • Coronavirus vaccine: Nov. 1st is when COVID-19 vaccine could be ready: CDC

    7:19

    Yahoo Finance's Adam Shapiro and Anjalee Khemlani speak with Dr. Harry Hildreth CEO of Meharry Medical College about the CDC news that a COVID-19 vaccine could be ready by November 1, 2020.
    #coronavirusvaccine #COVID19vaccine #coronavirus

    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com

  • When We Get The 1st Coronavirus Vaccine, How Well Will It Work? | Sunday TODAY

    4:37

    Vladimir Putin made headlines this week when he announced that Russia produced a coronavirus vaccine first and has plans to vaccinate 30 million Russians in October. This sparked skepticism in the medical community around the safety and efficacy. NBC’s Molly Hunter has this week’s Sunday Focus.
    » Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:
    Follow TODAY on Pinterest:

    #Coronavirus #Vaccine #SundayTODAY

    When We Get The 1st Coronavirus Vaccine, How Well Will It Work? | Sunday TODAY

  • Doubts surround Russia’s coronavirus vaccine

    3:14

    Russian President Vladimir Putin says a locally developed COVID-19 vaccine has been given regulatory approval after less than two months of testing on humans, but there are concerns safety could have been compromised for speed.

    Watch The National live on YouTube Sunday-Friday at 9 p.m. ET

    Subscribe to The National:


    Connect with The National online:
    Facebook |
    Twitter |
    Instagram |

    More from CBC News |

    The National is CBC's flagship nightly news program, featuring the day's top stories with in-depth and original journalism, with hosts Adrienne Arsenault and Andrew Chang in Toronto, Ian Hanomansing in Vancouver and the CBC's chief political correspondent, Rosemary Barton in Ottawa.

  • CDC tells officials to prepare to distribute COVID-19 vaccine by early November | WNT

    4:44

    The Centers for Disease Control and Prevention has outlined how officials should prepare to distribute a COVID-19 vaccine to health care workers and other high-risk groups this fall.

    WATCH THE FULL EPISODE OF 'WORLD NEWS TONIGHT':


    WATCH OTHER FULL EPISODES OF WORLD NEWS TONIGHT:


    WATCH WORLD NEWS TONIGHT ON HULU:


    #WorldNewsTonight #CDC #COVID19Vaccine

  • x
  • Pfizer enters phase three Covid-19 vaccine trial

    6:45

    CNBC's Meg Tirrell reports on Pfizer's coronavirus vaccine trial. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Brian Kelly and Jeff Mills. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    U.S. drugmaker Pfizer and German biotech BioNTech said they began their late-stage human trial for a potential coronavirus vaccine on Monday as pharmaceutical companies race to win regulatory approval before the end of the year.

    Shares of Pfizer rose more than 3% in after-hours trading Monday. BioNTech was up more than 2%.

    The trial will include up to 30,000 participants between the ages of 18 and 85 across 120 sites globally, including 39 U.S. states, the companies announced. If it is successful, they expect to submit it for final regulatory review as early as October. They plan to supply up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021.

    The decision to start the trial reflects “our primary goal to bring a well-tolerated, highly effective vaccine to the market as quickly as possible, while we will continue to evaluate our other vaccine candidates as part of a differentiated COVID-19 vaccine portfolio,” BioNTech CEO Ugur Sahin said in a release. “Many steps have been taken towards this important milestone and we would like to thank all those involved for their extraordinary commitment.”

    The companies’ experimental vaccine uses messenger ribonucleic acid, or mRNA molecules, to provoke an immune response to fight the virus. Scientists hope mRNA, which relays genetic instructions from DNA, can be used to train the immune system to recognize and destroy the virus.

    Earlier this month, the companies said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10- or 30-microgram doses.

    Last week, the U.S. government announced it would pay Pfizer and BioNTech $1.95 billion to produce and deliver 100 million doses of their vaccine if it proves safe and effective. The deal was signed as part of Operation Warp Speed, the Trump administration’s effort to accelerate development and production of vaccines and treatments to fight the coronavirus.

    Pfizer previously announced it hoped to start its pivotal late-stage trial of the vaccine as early as this week.

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:

    For info on the best credit cards go to CNBC Select:


    #CNBC
    #CNBCTV

  • Coronavirus vaccine: Russian COVID-19 vaccine shows to produce antibody response

    3:07

    Yahoo Finance's Anjalee Khemlani reports on the news of a coronavirus vaccine from Russia has produced an anitbody response.
    #coronavirusvaccine #COVID19vaccine #RussiaCOVID19vaccine
    This segment originally aired in August 5, 2020.
    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com

  • COVID 19 Vaccine Update with Professor Michael Mina, MD: Safety, Efficacy, Distribution, Trials

    8:42

    Harvard professor and epidemiologist Michael Mina MD, Ph.D. is back to give a COVID 19 Vaccine Update including:
    00:00 Attention to vaccine safety in phase one, two, and three trials
    00:21 Mild side effects from vaccines observed in phase 1 and 2 trials
    00:32 Awareness of fringe effects when the vaccine is introduced to thousands or millions
    00:59 Post-market surveillance of adverse effects vs. coincidence and confounding
    01:31 Ensuring efficacy - new territory with a coronavirus vaccine
    01:50 Sterilizing immunity
    02:06 Relatively weak immune response from coronaviruses vs severity
    02:29 Polio and measles vaccines create robust immunity
    02:59 New technology being used in some SARS-CoV-2 vaccines
    03:47 Cautious optimism about the efficacy of vaccines
    04:02 Herd immunity
    04:43 Who is going to get the COVID-19 vaccine first? Which countries?
    05:15 Medical professionals likely the first to receive vaccines
    06:02 Will COVID 19 vaccines block transmission and spread?
    06:10 Should kids get the vaccine?
    06:37 How well will vaccines work in the elderly and immunocompromised?
    07:46 How quickly can the COVID vaccines get distributed? By the end of this year?

    MedCram has no financial disclosures related to any medical products or vaccines, and from our understanding, Dr. Mina does not either.

    Michael Mina, MD Ph.D. is an Assistant Professor of Epidemiology, Immunology, and Infectious Diseases at Harvard T. H. Chan School of Public Health. Dr. Mina is also a core member of the Center for Communicable Disease Dynamics (CCDD) and an Associate Medical Director in Clinical Microbiology. Dr. Mina's bio is here:


    THE MEDCRAM WEBSITE:

    Visit us for videos on over 60 medical topics and CME / CEs for medical professionals:


    MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS:

    MedCram offers group discounts for students and a variety of medical programs, hospitals, and other institutions. Contact us at customers@medcram.com if you are interested.


    SUBSCRIBE TO THE MEDCRAM YOUTUBE CHANNEL:


    Get notified of new videos by hitting the bell icon:


    OTHER MEDCRAM VIDEOS FEATURING DR. MICHAEL MINA:

    COVID-19 Update 98 featured Dr. Mina's research about COVID 19 testing and how quickly identifying individuals who are contagious (and who have high levels of SARS-CoV-2 virus) should be the primary focus:

    A 5 minute summary with Dr. Mina of some key differences between COVID-19 antigen tests with rapid results:

    Interview with Dr. Mina on frequent rapid paper strip COVID 19 testing: Dr. Mina is the director of where you can get more info about at-home COVID 19 screening


    FOLLOW US ON SOCIAL MEDIA:






    DISCLAIMER:

    MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor.


    ------------------------------------------------------
    Video produced by Kyle Allred, Co-Founder of
    Contact Kyle or MedCram by emailing: customers@medcram.com

    #COVID19 #SARSCOV2 #Science

  • Moderna releases interim phase one vaccine results

    3:39

    CNBC's Meg Tirrell details the latest in the effort to develop a coronavirus vaccine as Moderna releases interim phase one data. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    Moderna’s potential coronavirus vaccine generated a promising immune response in elderly patients in an early stage clinical trial, the biotech firm announced Wednesday.

    The company tested its vaccine on 10 adults between the ages of 56 and 70 and 10 elderly adults aged 71 and older, Moderna said. Each participant received two 100 microgram doses of the vaccine 28 days apart.

    The volunteers produced neutralizing antibodies, which researchers believe are necessary to build immunity to the virus, and T-cells, Moderna said in its results, which have not yet been published in a peer-reviewed journal. Additionally, the antibodies that were produced were higher than those seen in people who have recovered from Covid-19.

    The vaccine also appeared to be well tolerated, with no serious adverse events reported, the company said. Some patients reported fatigue, chills, headaches and pain at the injection site, though the majority of symptoms resolved within two days, the company said.

    Shares of Moderna were up nearly 6% in intraday trading Wednesday. The company will hold a conference call at 4:30 p.m. ET to discuss the results.

    The vaccine from Moderna is one of several in development to fight the coronavirus, which has infected more than 23.9 million people worldwide and killed at least 820,100, according to data compiled by Johns Hopkins University. There are more than 170 vaccines in development worldwide, according to the World Health Organization. At least 31 are in clinical trials, the WHO said.

    U.S. health officials say there is no returning to “normal” until there is a vaccine.

    Moderna’s experimental vaccine contains genetic material called messenger RNA, or mRNA, which scientists hope provokes the immune system to fight the virus. In May, the company released preliminary data that showed the vaccine produced antibodies in 45 healthy adults.

    Scientists had previously cautioned that the phase one study was small, and the results may differ for other populations, including the elderly who generally mount a weaker immune response. The new data Wednesday will likely boost hopes that there could be a safe and effective vaccine to prevent Covid-19 by the end of the year or early 2021.

    Last month, the company started a phase three trial testing how safe and effective it is on 30,000 people with results expected as early as October. The company said it anticipates completing enrollment for its phase three trial in September.

    Moderna is charging between $32 and $37 per dose for its coronavirus vaccine for some customers, under cheaper “pandemic pricing,” it said earlier this month. At the time, the company said it was in discussion for larger volume agreements that will have a lower price.

    Earlier this month, President Donald Trump announced the U.S. government would purchase 100 million doses of Moderna’s vaccine in a deal worth $1.53 billion. The U.S. has already invested $955 million in Moderna’s vaccine development, bringing its total investment up to nearly $2.5 billion.

    While there is hope scientists will find a safe and effective vaccine, there is never a guarantee, scientists say. They warn that questions remain about how the human body responds once it’s been infected with the virus.

    One question among scientists is whether antibodies produced in response to Covid-19 offer protection against getting infected again.

    Scientists expect that antibodies provide some degree of protection against getting Covid-19, but they can’t say that definitively yet since the coronavirus was first discovered less than eight months ago. Hong Kong researchers on Monday reported what appears to be the first confirmed case of Covid-19 reinfection, a man who was first infected by the virus in late March and then, 4½ months later, seemingly contracted the virus again.

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:

    For info on the best credit cards go to CNBC Select:


    #CNBC
    #CNBCTV

  • Canada secures deals for up to 114M doses of potential COVID-19 vaccines

    15:25

    Canada's federal government has signed agreements with two U.S. drug companies to secure up to 114 million doses of potential COVID-19 vaccines under development.
    To read more:

    »»» Subscribe to CBC News to watch more videos:

    Connect with CBC News Online:

    For breaking news, video, audio and in-depth coverage:
    Find CBC News on Facebook:
    Follow CBC News on Twitter:
    For breaking news on Twitter:
    Follow CBC News on Instagram:

    Download the CBC News app for iOS:
    Download the CBC News app for Android:

    »»»»»»»»»»»»»»»»»»
    For more than 75 years, CBC News has been the source Canadians turn to, to keep them informed about their communities, their country and their world. Through regional and national programming on multiple platforms, including CBC Television, CBC News Network, CBC Radio, CBCNews.ca, mobile and on-demand, CBC News and its internationally recognized team of award-winning journalists deliver the breaking stories, the issues, the analyses and the personalities that matter to Canadians.

  • Russian coronavirus vaccine: No data has come out that it is safe and effective: Physician

    5:44

    On Tuesday, President Putin announced that Russia had approved the ‘world’s first’ coronavirus vaccine, although many in the heath community remain skeptical as the vaccine has yet to finish phase 3 trials. Dr. Angela Rasmussen, a virologist at Columbia University, joins The Final Round panel to discuss the coronavirus vaccine race.
    #coronavirus #Russianvaccine #RussiaCOVID19
    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:

  • UK sees 100,000 sign up for COVID-19 vaccine tests

    2:40

    More Britons are being urged to contribute to future vaccine candidate trials after an initial 100,000 volunteers signed up.

    Those who add themselves to the registry can be contacted by researchers organising large-scale clinical trials of coronavirus vaccines.

    SUBSCRIBE to our YouTube channel for more videos:

    Follow us on Twitter:

    Like us on Facebook:

    Follow us on Instagram:

    For more content go to and download our apps:

    Apple:

    Android

    Sky News videos are now available in Spanish here/Los video de Sky News están disponibles en español aquí

  • Could “challenge trials” speed coronavirus vaccine development? - BBC News

    3:26

    Scientists have warned it could be many months, before we know if any of the coronavirus vaccines currently undergoing trials are effective. One way to speed up the process, would be if so-called 'challenge trials' are allowed, where volunteers are given the vaccine and then deliberately infected with coronavirus, to see if they're protected. But some experts aren’t convinced such trials are safe or necessary. Our Medical Editor Fergus Walsh reports.

    Please subscribe HERE

  • Operation Warp Speed chief advisor lays out coronavirus vaccine timeline

    5:06

    Moncef Slaoui, White House chief advisor of Operation Warp Speed, joins Squawk on the Street to discuss developments in a Coronavirus vaccine. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    The United States could immunize Americans “most susceptible” to Covid-19 by December if a vaccine is approved before then, President Donald Trump’s coronavirus vaccine czar told CNBC on Monday.

    The U.S. could also immunize “most of the elderly” and health-care workers in January, Dr. Moncef Slaoui, who is leading the Trump administration’s Covid-19 vaccine program Operation Warp Speed, said in a “Squawk on the Street” interview. The rest of the public would get a vaccine sometime in January, February, March and April, he added.

    Covid-19 vaccine development is progressing “very well,” he said, with the U.S. already investing in 25 different manufacturing facilities to help produce six potential vaccines. The U.S. has spent billions on six vaccine candidates, including ones from Moderna, Pfizer and AstraZeneca, which are currently in late-stage testing.

    “We are already stockpiling small amounts of vaccine doses that could become readily available in November or in December,” he said.

    Slaoui’s remark came shortly after Trump reiterated on “Fox News” on Monday that the U.S. could have a Covid-19 vaccine by the end of October. On Friday, he said the U.S. will manufacture at least 100 million coronavirus vaccine doses before the end of the year and have enough to inoculate every American by April.

    Asked which drugmaker could be the first to be approved, Trump said Monday that Pfizer, Moderna and AstraZeneca are progressing well. He added Johnson & Johnson’s vaccine will “probably be a little later.”

    U.S. health officials have repeatedly said they don’t expect to find a safe and effective vaccine until the end of the year or early 2021, though there is never a guarantee. Trump’s vaccine forecast has added to concerns from infectious disease experts and scientists that he is pressuring U.S. regulators to approve a vaccine before it’s been adequately tested.

    On Sept. 8, nine drug companies in an unusual move released a letter pledging that they would prioritize safety and uphold “the integrity of the scientific process” in their efforts to develop coronavirus vaccines.

    Dr. Stephen Hahn, the commissioner of the Food and Drug Administration, also addressed political concerns, telling the Economic Club on Sept. 10 that he has “no intention” of overruling career scientists at the FDA on a vaccine approval.

    Earlier this month, Slaoui told Science Magazine that he would “immediately resign” if there were undue interference in this process.

    “I’m out,” he said, according to a transcript of the interview. “I have to say there has been absolutely no interference. Despite my past, which is still my present, I am still the same person with the same values. The pandemic is much bigger than that. Before being a political person with convictions, humanity has always been my objective.”

    When asked by CNBC on Monday whether he would publicly take a vaccine once it’s been granted emergency use authorization or approval, Slaoui said, “Certainly.”

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:

    For info on the best credit cards go to CNBC Select:


    #CNBC
    #CNBCTV

  • Coronavirus Vaccine: NYUs Dr. Robyn Gershon talks COVID-19 vaccine concerns

    7:44

    Robyn Gershon, Clinical Professor of Epidemiology at New York University’s School of Public Health discusses COVID-19 concerns.
    #Coronavirus #COVID-19 #coronavirusvaccine

    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    About Yahoo Finance Premium: With a subscription to Yahoo Finance Premium, get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
    To learn more about Yahoo Finance Premium please visit:

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com
    Follow Yahoo Finance Premium on Twitter:

  • Coronavirus vaccine: FDAs new COVID-19 vaccine safeguards

    8:30

    Rheumatologist Dr. Kanika Monga joins Yahoo finance's Kristin Myers to discuss the new joint safety pledge signed by COVID-19 vaccine makers.
    #coronavirusvaccine #COVID19vaccine #COVID19
    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com

  • Coronavirus vaccine: CDC releases plans to make COVID-19 vaccines free for all in the United States

    2:33

    Yahoo Finance's Anjalee Khemlani reports on the latest news on vaccine distribution in the United States.
    #coronavirusvaccine #COVID19vaccine #coronavirus

    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    About Yahoo Finance Premium: With a subscription to Yahoo Finance Premium, get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
    To learn more about Yahoo Finance Premium please visit:

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com
    Follow Yahoo Finance Premium on Twitter:

  • Biotech lab develops blueprint to fast-track coronavirus vaccine production

    2:06

    Drugmaker AstraZeneca's vaccine is now in advanced trials and the company says it has the capacity to make 3 billion doses when the vaccine is ready. Charlie D'Agata has the latest in CBS News' series Racing to a Cure.

    Subscribe to the CBS Evening News Channel HERE:
    Watch Full Episodes of the CBS Evening News HERE:
    Watch the latest installment of On the Road, only on the CBS Evening News, HERE:
    Follow CBS Evening News on Instagram:
    Like CBS Evening News on Facebook HERE:
    Follow the CBS Evening News on Twitter HERE:
    Follow the CBS Evening News on Google+ HERE:

    Get your news on the go! Download CBS News mobile apps HERE:

    Get new episodes of shows you love across devices the next day, stream local news live, and watch full seasons of CBS fan favorites anytime, anywhere with CBS All Access. Try it free!

    ---
    The CBS Evening News premiered as a half-hour broadcast on Sept. 2, 1963. Check local listings for CBS Evening News broadcast times.

  • COVID-19 vaccine: Safety concerns as countries rush for cure

    2:25

    There are more than 150 coronavirus vaccines in development around the world.
    But fewer than 10 have reached stage three, the final phase before approval and eventual production and distribution.
    There are worries the rush for a vaccine means safety is being compromised, as Al Jazeera's Gabriel Elizondo reports from New York, US.

    - Subscribe to our channel:
    - Follow us on Twitter:
    - Find us on Facebook:
    - Check our website:

    #AlJazeeraEnglish #Coronavirus #Vaccine

  • Coronavirus vaccine: Americans could get COVID-19 vaccine by end of 2020: Pfizer CEO

    1:42

    Yahoo Finance's Anjalee Khemlani breaks down the latest statement from Pfizer CEO Albert Bourla that a vaccine could be available by the end of 2020.

    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    About Yahoo Finance Premium: With a subscription to Yahoo Finance Premium, get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
    To learn more about Yahoo Finance Premium please visit:

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com
    Follow Yahoo Finance Premium on Twitter:

  • Drugmakers sign safety pledge amid race to develop coronavirus vaccine

    2:43

    The CEOs of nine drugmakers vowed not to seek approval for coronavirus vaccines until they're proved safe and effective. Meanwhile, AstraZeneca paused its closely-watched vaccine trial after one participant developed a possible adverse reaction. Adriana Diaz has the details.

    Subscribe to the CBS Evening News Channel HERE:
    Watch Full Episodes of the CBS Evening News HERE:
    Watch the latest installment of On the Road, only on the CBS Evening News, HERE:
    Follow CBS Evening News on Instagram:
    Like CBS Evening News on Facebook HERE:
    Follow the CBS Evening News on Twitter HERE:
    Follow the CBS Evening News on Google+ HERE:

    Get your news on the go! Download CBS News mobile apps HERE:

    Get new episodes of shows you love across devices the next day, stream local news live, and watch full seasons of CBS fan favorites anytime, anywhere with CBS All Access. Try it free!

    ---
    The CBS Evening News premiered as a half-hour broadcast on Sept. 2, 1963. Check local listings for CBS Evening News broadcast times.

  • Coronavirus vaccine may not be ready by November, also COVID-19 tests to be offered by some airlines

    5:42

    Anjalee Khemlani breaks down the latest news on the coronavirus timeline.
    #coronavirus #COVID19vaccine #COVID-19

    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    About Yahoo Finance Premium: With a subscription to Yahoo Finance Premium, get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
    To learn more about Yahoo Finance Premium please visit:

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com
    Follow Yahoo Finance Premium on Twitter:

  • Coronavirus vaccine: Can your employer force you to get a COVID-19 vaccine?

    5:23

    Polsinelli Principal Lindsay Ryan and Yahoo Finance's Zack Guzman discuss whether employers are legally allowed to mandate workers to get a vaccine for the coronavirus.
    #coronavirus #COVID19 #coronavirusvaccine

    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com

  • Coronavirus vaccine: Heres why the first COVID-19 might not be the most effective

    7:17

    Dr. Cindy Prins, University of Florida Associate Professor of Epidemiology joins Yahoo Finance’s On The Move panel to break down the latest developments on a potential coronavirus vaccine.
    #coronavirusvaccine #COVID19vaccine #coronavirus
    This segment originally aired on September 4, 2020.
    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com

  • Coronavirus vaccine: 35% of Americans unwilling to get COVID-19 vaccine: Poll

    8:20

    Emergency medicine physician assistant Dr. Alison Haddock discusses the poll which suggest that over a third of Americans are reluctant to get the COVID-19 vaccination. Also, Dr. Haddock discusses the timeline and development for vaccines in Russia and the United States.
    #coronavirusvaccination #COVID19vaccine #Russia

    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:

  • Coronavirus vaccine: Moderna is in talks with Japan for 40 million doses of COVID-19 vaccine

    2:04

    Yahoo Finance's Ines Ferre reports on Japan purchasing 40 million doses of a COVID-19 vaccine from Moderna.
    #coronavirusvaccine #COVID19 #Moderna

    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com

  • 新型コロナウイルスのワクチン開発には、なぜ時間がかかるのか? その理由を専門家が解説 | WIRED.jp

    10:00

    新型コロナウイルスのワクチン開発が急ピッチで進められているが、一般的なワクチンの開発には10年から15年かかるとされる。年内の実用化を期待する声もあるが、果たして史上最速のワクチン開発は実現するのか? 医師でスタンフォード大学スタンフォード・ヘルスコミュニケーション・イニシアチヴ所長のシーマ・ヤスミン博士が解説する。

    記事はこちら:

    WIRED JAPAN チャンネル登録はこちら▶︎▶︎

    WIRED JAPAN


    WIRED.jp Twitter


    WIRED.jp Facebook


    WIRED.jp LINE

  • Race for coronavirus vaccine intensifies

    5:10

    Scientists' goal is to develop a vaccine that is safe and effective.

    #vaccine #scientists #covid19

  • Coronavirus vaccine: AstraZeneca pauses trial after unexplained illness arises

    2:35

    AstraZeneca COVID-19 vaccine trials are now on hold, after an unexplained illness arose in one of the participants. Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Anjalee Khemlani break down the details.

    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com

  • What happens after a COVID-19 vaccine is available?

    4:54

    An epidemiologist and infectious disease specialist answer questions about a COVID-19 vaccine, including what happens after a vaccine is approved and available in Canada.

    Watch The National live on YouTube Sunday-Friday at 9 p.m. ET

    Subscribe to The National:


    Connect with The National online:
    Facebook |
    Twitter |
    Instagram |

    More from CBC News |

    The National is CBC's flagship nightly news program, featuring the day's top stories with in-depth and original journalism, with hosts Adrienne Arsenault and Andrew Chang in Toronto, Ian Hanomansing in Vancouver and the CBC's chief political correspondent, Rosemary Barton in Ottawa.

  • Coronavirus vaccine: Astrazeneca launching late stage COVID-19 trial

    2:17

    Yahoo Finance's Anjalee Khemlani breaks down the latest news on the Astrazeneca late stage vaccine trial.
    #coroanvirusvaccine #COVID19vaccine #COVID19vaccine

    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com

  • Coronavirus vaccine timeline: Johnson & Johnson executive breaks down COVID-19 vaccine development

    8:40

    Johnson & Johnson Executive Committee Vice-Chair and Chief Scientific Officer Dr. Paul Stoffels speaks with Yahoo Finance about the development of the COVID-19 vaccine.
    #COVID19vaccine #coronavirusvaccine #COVID19
    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:

  • Coronavirus vaccine: J&J enrolls 60K people for vaccine trials, WHO warns of resurgence in Europe

    3:13

    Yahoo Finance's Anjalee Khemlani breaks down the latest news on the COVID-19 vaccine, teachers threatening to strike in New York and Detroit, and the World Health Organization warning of a resurgence of coronavirus in Europe.
    #COVID19vaccine #coronavirus #COVID-19
    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:

  • Army official optimistic about COVID-19 vaccine in 2020

    4:02

    Under Secretary of the Army James McPherson addresses the military’s involvement in Operation Warp Speed.

    #GMA3 #Pandemic #Military #Army #CovidVaccine

  • Dr. Gregory Poland - Phase 3 clinical trial of COVID 19 vaccine underway

    1:57

    As the race to develop a safe and effective vaccine to protect against COVID-19 continues, phase 3 trials of investigational vaccines are underway. In this Q&A, Dr. Gregory Poland, an infectious diseases expert and head of Mayo Clinic's Vaccine Research Group, explains the meaning of phase 3, who’s being tested and the hopeful outcomes.

Shares

x

Check Also

Menu